Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

por Kotasek, Dusan, Tebbutt, Niall, Desai, Jayesh, Welch, Stephen, Siu, Lillian L, McCoy, Sheryl, Sun, Yu-Nien, Johnson, Jessica, Adewoye, Adeboye H, Price, Timothy
Publicado 2011

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

por Rosen, Lee S, Lipton, Lara, Price, Timothy J, Belman, Neil D, Boccia, Ralph V, Hurwitz, Herbert I, Stephenson Jr, Joe J, Wirth, Lori J, McCoy, Sheryl, Hei, Yong-jiang, Hsu, Cheng-Pang, Tebbutt, Niall C
Publicado 2013

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors

por Benjamin, Robert S., Schöffski, Patrick, Hartmann, Jörg Thomas, Van Oosterom, Allan, Bui, Binh Nguyen, Duyster, Justus, Schuetze, Scott, Blay, Jean-Yves, Reichardt, Peter, Rosen, Lee S., Skubitz, Keith, McCoy, Sheryl, Sun, Yu-Nien, Stepan, Daniel E., Baker, Laurence
Publicado 2010